12 May 2026

CRC Research Update — May 12, 2026

Creator: The CRC Digest
Published: 2026-05-12T13:27:42Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

COLOSOTO Trial Tests Sotorasib Combo in KRAS G12C Colorectal Cancer
A phase II trial is evaluating sotorasib plus panitumumab and 5-FU as first-line therapy for metastatic colorectal cancer with KRAS G12C mutations, targeting a historically difficult-to-treat subgroup. (Oncodaily)
High MAPK, Low WNT Cell State Drives Metastasis in Colorectal Cancer
Researchers using a mouse model found that highly metastatic colorectal cancer cells show increased MAPK pathway activity and suppressed WNT signaling, and that pharmacological inhibition of mutant KRAS reduced both lung and liver metastases. (Nature Cancer)
Sigmoidoscopy Screening Shows 23-Year Benefit for Colorectal Cancer
A randomized trial from Norway found that once-only sigmoidoscopy screening continued to reduce colorectal cancer incidence and death over 23 years of follow-up, extending the known benefits beyond the previously reported 15-year window. (Annals of Internal Medicine)
Sequential vs. Upfront Oxaliplatin in Metastatic Colorectal Cancer: Long-Term Results
(Communications Medicine)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

Prolonged Response to Pembrolizumab in BRAF V600E MSS Colorectal Cancer
A patient with BRAF V600E-mutant microsatellite-stable metastatic colorectal cancer achieved a prolonged response to pembrolizumab following a dynamic increase in tumor mutational burden. (The Oncologist)
Nous-209 Immunotherapy Targets Appear Early in Lynch Syndrome Precancers
In a study of Lynch syndrome carriers, 83% of advanced adenomas and 58% of adenomas were mismatch repair-deficient, and the presence of Nous-209 mutations correlated strongly with microsatellite instability status, suggesting potential for preventive immunotherapy. (Cancer Prevention Research)

🔎 Screening Watch

Screening guidelines, early detection, and prevention advances

Five Decades of Familial Adenomatous Polyposis Surveillance in Denmark
A study from the Danish Polyposis Register emphasizes the importance of lifelong endoscopic surveillance and tailored treatment strategies for FAP patients, who face elevated risks for duodenal and pancreatic cancers even after colectomy. (APMIS)
Circulating Tumor DNA Shows Promise for Predicting Colorectal Cancer Recurrence
A review of current evidence suggests circulating tumor DNA has significant prognostic and predictive potential for detecting minimal residual disease and individualizing adjuvant therapy in colorectal cancer. (Klinická Onkologie)

These findings highlight progress across treatment, prevention, and our understanding of colorectal cancer biology. Stay informed and discuss any questions with your care team.

CRC Research Update

Subscribe to The CRC Digest